Evolutec (LSE:EVC) said it will discontinue development of rEV131 after the histamine binding protein missed the primary endpoint of reduction in inflammation at 14 days post-surgery vs. placebo in a double-blind, U.S. Phase II trial...
Evolutec (LSE:EVC) said it will discontinue development of rEV131 after the histamine binding protein missed the primary endpoint of reduction in inflammation at 14 days post-surgery vs. placebo in a double-blind, U.S. Phase II trial...